XXXX in relation to antiretroviral status among @entity791 @entity1 from south India.

@entity1 @entity5253 @entity16333 @entity5198 @entity1292 @entity378 @entity791 @entity6926
BACKGROUND: There is a need to generate data from India on relative frequencies of specific @entity1292 ( @entity1292 ) in different regions and their relation to the choice of commonly used generic highly active anti-retroviral therapy (HAART) regimens. OBJECTIVES: To document the prevailing prevalence pattern of @entity1292 both before and after HAART, to look for reduction in @entity1292 following HAART, to assess the risk of developing new @entity1292 within 6 months of HAART initiation and to see if there is any difference in the risk of developing a new @entity6926 within 6 months of HAART initiation, for those on Efavirenz (EFV)-based regimens and @entity5198 ( @entity16333 )-based regimens. MATERIALS AND METHODS: In a prospective observational cohort study conducted in South India involving 108 ART-naive @entity791 @entity1 , different pathogens were isolated and identified using standard laboratory techniques. Data analysis was done using SPSS software (version 16.0). Risk of developing an @entity6926 after HAART initiation was assessed using the likelihood ratio test from Cox regression models. RESULTS: @entity378 (53.4%), @entity5253 (14.7%) were the common infections seen. There was a drastic reduction of 96.59% in @entity6926 events after 6 months of HAART. The risk of developing an @entity6926 within 6 months of HAART initiation was 5.56%. Time to development of an @entity6926 in the first 6 months of HAART was shorter for the @entity16333 -based regimens than with EFV-based regimens, but this difference was not statistically significant (HR=0.891, 95% CI: 0.179-4.429; P=0.888). CONCLUSION: @entity378 is the most important @entity6926 before initiation of HAART. Both EFV and @entity16333 -based regimens are equally efficacious in controlling @entity1292 .
